Download PDF
CC BY-NC-ND 4.0 · Thromb Haemost 2022; 122(07): 1085-1095
DOI: 10.1055/a-1701-2809
Review Article

Pathophysiology of Antiphospholipid Syndrome

David Green
1   Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

The antiphospholipid syndrome is characterized by antibodies directed against phospholipid-binding proteins and phospholipids attached to cell membrane receptors, mitochondria, oxidized lipoproteins, and activated complement components. When antibodies bind to these complex antigens, cells are activated and the coagulation and complement cascades are triggered, culminating in thrombotic events and pregnancy morbidity that further define the syndrome. The phospholipid-binding proteins most often involved are annexins II and V, β2-glycoprotein I, prothrombin, and cardiolipin. A distinguishing feature of the antiphospholipid syndrome is the “lupus anticoagulant.” This is not a single entity but rather a family of antibodies directed against complex antigens consisting of β2-glycoprotein I and/or prothrombin bound to an anionic phospholipid. Although these antibodies prolong in vitro clotting times by competing with clotting factors for phospholipid binding sites, they are not associated with clinical bleeding. Rather, they are thrombogenic because they augment thrombin production in vivo by concentrating prothrombin on phospholipid surfaces. Other antiphospholipid antibodies decrease the clot-inhibitory properties of the endothelium and enhance platelet adherence and aggregation. Some are atherogenic because they increase lipid peroxidation by reducing paraoxonase activity, and others impair fetal nutrition by diminishing placental antithrombotic and fibrinolytic activity. This plethora of destructive autoantibodies is currently managed with immunomodulatory agents, but new approaches to treatment might include vaccines against specific autoantigens, blocking the antibodies generated by exposure to cytoplasmic DNA, and selective targeting of aberrant B-cells to reduce or eliminate autoantibody production.

Keywords

antiphospholipid antibodies - phospholipid-binding proteins - lupus anticoagulant


Publication History

Received: 01 September 2021

Accepted: 03 November 2021

Accepted Manuscript online:
18 November 2021

Article published online:
17 January 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Hughes GRV. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J (Clin Res Ed) 1983; 287 (6399): 1088-1089
    CrossrefPubMedGoogle Scholar
  • 2 Tonello M, Bison E, Cattini MG. et al. Anti-phosphatidyl-serine/prothrombin antibodies (aPS/PT) in isolated lupus anticoagulant (LA): is their presence linked to dual test positivity?. Clin Chem Lab Med 2021; 59 (12) 1950-1953
    CrossrefPubMedGoogle Scholar
  • 3 Oosting JD, Derksen RHWM, Bobbink IWG, Hackeng TM, Bouma BN, de Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism?. Blood 1993; 81 (10) 2618-2625
    CrossrefPubMedGoogle Scholar
  • 4 Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med 2013; 368 (11) 1033-1044
    CrossrefPubMedGoogle Scholar
  • 5 Triplett DA, Brandt JT, Musgrave KA, Orr CA. The relationship between lupus anticoagulants and antibodies to phospholipid. JAMA 1988; 259 (04) 550-554
    CrossrefPubMedGoogle Scholar
  • 6 Greaves M. Antiphospholipid antibodies and thrombosis. Lancet 1999; 353 (9161): 1348-1353
    CrossrefPubMedGoogle Scholar
  • 7 Campbell AL, Pierangeli SS, Wellhausen S, Harris EN. Comparison of the effects of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation. Thromb Haemost 1995; 73 (03) 529-534
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Forastiero RR, Martinuzzo ME, De Larrañaga G, Broze GJ. Antibodies to tissue factor pathway inhibitor are uncommonly detected in patients with infection-related antiphospholipid antibodies. J Thromb Haemost 2003; 1 (10) 2250-2251
    CrossrefPubMedGoogle Scholar
  • 9 Forastiero RR, Martinuzzo ME, Broze Jr GJ. High titers of autoantibodies to tissue factor pathway inhibitor are associated with the antiphospholipid syndrome. J Thromb Haemost 2003; 1 (04) 718-724
    CrossrefPubMedGoogle Scholar
  • 10 Zhang Y, Xiao M, Zhang S. et al. Coagulopathy and antiphospholipid antibodies win patients with covid-19. N Engl J Med 2020; 382 (17) e38
    CrossrefPubMedGoogle Scholar
  • 11 Harzallah I, Debliquis A, Drénou B. Lupus anticoagulant is frequent in patients with Covid-19. J Thromb Haemost 2020; 18 (08) 2064-2065
    CrossrefPubMedGoogle Scholar
  • 12 Bowles L, Platton S, Yartey N. et al. Lupus anticoagulant and abnormal coagulation tests in patients with Covid-19. N Engl J Med 2020; 383 (03) 288-290
    CrossrefPubMedGoogle Scholar
  • 13 Jones DW, Gallimore MJ, Harris SL, Winter M. Antibodies to factor XII associated with lupus anticoagulant. Thromb Haemost 1999; 81 (03) 387-390
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Zuo Y, Estes SK, Ali RA. et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Transl Med 2020; 12 (570) eabd3876
    CrossrefPubMedGoogle Scholar
  • 15 Al-Samkari H, Karp Leaf RS, Dzik WH. et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood 2020; 136 (04) 489-500
    CrossrefPubMedGoogle Scholar
  • 16 Klok FA, Kruip MJHA, van der Meer NJM. et al. Incidence of thrombotic complications in critically ill ICU patients with Covid-19. Thromb Res 2020; 191: 145-147
    CrossrefPubMedGoogle Scholar
  • 17 Althaus K, Marini I, Zlamal J. et al. Antibody-induced procoagulant platelets in severe COVID-19 infection. Blood 2021; 137 (08) 1061-1071
    CrossrefPubMedGoogle Scholar
  • 18 Rapkiewicz AV, Mai X, Cardsons SE. et al. Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in Covid-19: a case series. EClinicalMedicine 2020; 24: 100434
    CrossrefPubMedGoogle Scholar
  • 19 Borghi MO, Beltagy A, Garrafa E. et al. Anti-phospholipid antibodies in COVID-19 are different from those detectable in the anti-phospholipid syndrome. Front Immunol 2020; 11: 584241
    CrossrefPubMedGoogle Scholar
  • 20 Connell NT, Battinelli EM, Connors JM. Coagulopathy of COVID-19 and antiphospholipid antibodies. J Thromb Haemost 2020; DOI: 10.1111/JTH.14893.
    CrossrefPubMedGoogle Scholar
  • 21 Brownstein C, Deora AB, Jacovina AT. et al. Annexin II mediates plasminogen-dependent matrix invasion by human monocytes: enhanced expression by macrophages. Blood 2004; 103 (01) 317-324
    CrossrefPubMedGoogle Scholar
  • 22 Zhang J, McCrae KR. Annexin A2 mediates endothelial cell activation by antiphospholipid/anti-β2 glycoprotein I antibodies. Blood 2005; 105 (05) 1964-1969
    CrossrefPubMedGoogle Scholar
  • 23 Romay-Penabad Z, Montiel-Manzano MG, Shilagard T. et al. Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo. Blood 2009; 114 (14) 3074-3083
    CrossrefPubMedGoogle Scholar
  • 24 Andree HAM, Stuart MC, Hermens WT. et al. Clustering of lipid-bound annexin V may explain its anticoagulant effect. J Biol Chem 1992; 267 (25) 17907-17912
    CrossrefPubMedGoogle Scholar
  • 25 de Laat B, Wu X-X, van Lummel M, Derksen RHWM, de Groot PG, Rand JH. Correlation between antiphospholipid antibodies that recognize domain I of β2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood 2007; 109 (04) 1490-1494
    CrossrefPubMedGoogle Scholar
  • 26 Rajagopalan S, Somers EC, Brook RD. et al. Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood 2004; 103 (10) 3677-3683
    CrossrefPubMedGoogle Scholar
  • 27 Rand JH, Wu X-X, Andree HAM. et al. Pregnancy loss in the antiphospholipid-antibody syndrome–a possible thrombogenic mechanism. N Engl J Med 1997; 337 (03) 154-160
    CrossrefPubMedGoogle Scholar
  • 28 Agar C, van Os GMA, Mörgelin M. et al. β2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood 2010; 116 (08) 1336-1343
    CrossrefPubMedGoogle Scholar
  • 29 de Laat B, Derksen RHWM, Urbanus RT, de Groot PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of β 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005; 105 (04) 1540-1545
    CrossrefPubMedGoogle Scholar
  • 30 Noordermeer T, Molhoek JE, Schutgens REG. et al. Anti-β2-glycoprotein I and anti-prothrombin antibodies cause lupus anticoagulant through different mechanisms of action. J Thromb Haemost 2021; 19 (04) 1018-1028
    CrossrefPubMedGoogle Scholar
  • 31 de Groot PG, Meijers JC. β(2) -Glycoprotein I: evolution, structure and function. J Thromb Haemost 2011; 9 (07) 1275-1284
    CrossrefPubMedGoogle Scholar
  • 32 Merrill JT, Zhang HW, Shen C. et al. Enhancement of protein S anticoagulant function by β2-glycoprotein I, a major target antigen of antiphospholipid antibodies: β2-glycoprotein I interferes with binding of protein S to its plasma inhibitor, C4b-binding protein. Thromb Haemost 1999; 81 (05) 748-757
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990; 112 (09) 682-698
    CrossrefPubMedGoogle Scholar
  • 34 Harris EN, Loizou S, Englert H. et al. Anticardiolipin antibodies and lupus anticoagulant. Lancet 1984; 2 (8411): 1099
    CrossrefPubMedGoogle Scholar
  • 35 Ortona E, Capozzi A, Colasanti T. et al. Vimentin/cardiolipin complex as a new antigenic target of the antiphospholipid syndrome. Blood 2010; 116 (16) 2960-2967
    CrossrefPubMedGoogle Scholar
  • 36 Vega-Ostertag M, Casper K, Swerlick R, Ferrara D, Harris EN, Pierangeli SS. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum 2005; 52 (05) 1545-1554
    CrossrefPubMedGoogle Scholar
  • 37 Espinola RG, Liu X, Colden-Stanfield M, Hall J, Harris EN, Pierangeli SS. E-Selectin mediates pathogenic effects of antiphospholipid antibodies. J Thromb Haemost 2003; 1 (04) 843-848
    CrossrefPubMedGoogle Scholar
  • 38 Comfurius P, Bevers EM, Galli M, Zwaal RFA. Regulation of phospholipid asymmetry and induction of antiphospholipid antibodies. Lupus 1995; 4 (Suppl. 01) S19-S22
    CrossrefPubMedGoogle Scholar
  • 39 Müller-Calleja N, Hollerbach A, Royce J. et al. Lipid presentation by the protein C receptor links coagulation with autoimmunity. Science 2021; 371 (6534): 1121-1134
    CrossrefPubMedGoogle Scholar
  • 40 Kaplan MJ. Linking clotting and autoimmunity. Science 2021; 371 (6534): 1100-1101
    CrossrefPubMedGoogle Scholar
  • 41 Jy W, Tiede M, Bidot CJ. et al. Platelet activation rather than endothelial injury identifies risk of thrombosis in subjects positive for antiphospholipid antibodies. Thromb Res 2007; 121 (03) 319-325
    CrossrefPubMedGoogle Scholar
  • 42 Carreras LO, Defreyn G, Machin SJ. et al. Arterial thrombosis, intrauterine death and “lupus” antiocoagulant: detection of immunoglobulin interfering with prostacyclin formation. Lancet 1981; 1 (8214): 244-246
    CrossrefPubMedGoogle Scholar
  • 43 Schorer AE, Duane PG, Woods VL, Niewoehner DE. Some antiphospholipid antibodies inhibit phospholipase A2 activity. J Lab Clin Med 1992; 120 (01) 67-77
    PubMedGoogle Scholar
  • 44 McCrae KR, DeMichele A, Samuels P. et al. Detection of endothelial cell-reactive immunoglobulin in patients with anti-phospholipid antibodies. Br J Haematol 1991; 79 (04) 595-605
    CrossrefPubMedGoogle Scholar
  • 45 Hulstein JJJ, Lenting PJ, de Laat B, Derksen RHWM, Fijnheer R, de Groot PG. β2-Glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation. Blood 2007; 110 (05) 1483-1491
    CrossrefPubMedGoogle Scholar
  • 46 Romay-Penabad Z, Aguilar-Valenzuela R, Urbanus RT. et al. Apolipoprotein E receptor 2 is involved in the thrombotic complications in a murine model of the antiphospholipid syndrome. Blood 2011; 117 (04) 1408-1414
    CrossrefPubMedGoogle Scholar
  • 47 Ramesh S, Morrell CN, Tarango C. et al. Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via β2GPI and apoER2. J Clin Invest 2011; 121 (01) 120-131
    CrossrefPubMedGoogle Scholar
  • 48 Sacharidou A, Chambliss KL, Ulrich V. et al. Antiphospholipid antibodies induce thrombosis by PP2A activation via apoER2-Dab2-SHC1 complex formation in endothelium. Blood 2018; 131 (19) 2097-2110
    CrossrefPubMedGoogle Scholar
  • 49 Ames PRJ, Batuca JR, Ciampa A, Iannaccone L, Delgado Alves J. Clinical relevance of nitric oxide metabolites and nitrative stress in thrombotic primary antiphospholipid syndrome. J Rheumatol 2010; 37 (12) 2523-2530
    CrossrefPubMedGoogle Scholar
  • 50 Comellas-Kirkerup L, Hernández-Molina G, Cabral AR. Antiphospholipid-associated thrombocytopenia or autoimmune hemolytic anemia in patients with or without definite primary antiphospholipid syndrome according to the Sapporo revised classification criteria: a 6-year follow-up study. Blood 2010; 116 (16) 3058-3063
    CrossrefPubMedGoogle Scholar
  • 51 Pontara E, Banzato A, Bison E. et al. Thrombocytopenia in high-risk patients with antiphospholipid syndrome. J Thromb Haemost 2018; 16 (03) 529-532
    CrossrefPubMedGoogle Scholar
  • 52 Nojima J, Suehisa E, Kuratsune H. et al. Platelet activation induced by combined effects of anticardiolipin and lupus anticoagulant IgG antibodies in patients with systemic lupus erythematosus–possible association with thrombotic and thrombocytopenic complications. Thromb Haemost 1999; 81 (03) 436-441
    Article in Thieme ConnectPubMedGoogle Scholar
  • 53 Lellouche F, Martinuzzo M, Said P, Maclouf J, Carreras LO. Imbalance of thromboxane/prostacyclin biosynthesis in patients with lupus anticoagulant. Blood 1991; 78 (11) 2894-2899
    CrossrefPubMedGoogle Scholar
  • 54 Proulle V, Furie RA, Merrill-Skoloff G, Furie BC, Furie B. Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS. Blood 2014; 124 (04) 611-622
    CrossrefPubMedGoogle Scholar
  • 55 Escolar G, Font J, Reverter JC. et al. Plasma from systemic lupus erythematosus patients with antiphospholipid antibodies promotes platelet aggregation. Studies in a perfusion system. Arterioscler Thromb 1992; 12 (02) 196-200
    CrossrefPubMedGoogle Scholar
  • 56 Hell L, Lurger K, Mauracher L-M. et al. Altered platelet proteome in lupus anticoagulant (LA)-positive patients-protein disulfide isomerase and NETosis as new players in LA-related thrombosis. Exp Mol Med 2020; 52 (01) 66-78
    CrossrefPubMedGoogle Scholar
  • 57 Ho YC, Ahuja KDK, Körner H, Adams MJ. β2GPI-anti-β2GPI antibodies and platelets: key players in the anti-phospholipid syndrome. Antibodies (Basel) 2016; 5 (02) 12
    CrossrefPubMedGoogle Scholar
  • 58 Sikara MP, Routsias JG, Samiotaki M, Panayotou G, Moutsopoulos HM, Vlachoyiannopoulos PG. beta2 Glycoprotein I (beta2GPI) binds platelet factor 4 (PF4): implications for the pathogenesis of antiphospholipid syndrome. Blood 2010; 115 (03) 713-723
    CrossrefPubMedGoogle Scholar
  • 59 Lutters BC, Derksen RH, Tekelenburg WL, Lenting PJ, Arnout J, de Groot PG. Dimers of beta 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2′. J Biol Chem 2003; 278 (36) 33831-33838
    CrossrefPubMedGoogle Scholar
  • 60 Shi T, Giannakopoulos B, Yan X. et al. Anti-β2-glycoprotein I antibodies in complex with β2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V. Arthritis Rheum 2006; 54 (08) 2558-2567
    CrossrefPubMedGoogle Scholar
  • 61 Ames PRJ, Antinolfi I, Scenna G, Gaeta G, Margaglione M, Margarita A. Atherosclerosis in thrombotic primary antiphospholipid syndrome. J Thromb Haemost 2009; 7 (04) 537-542
    CrossrefPubMedGoogle Scholar
  • 62 Pennings MT, van Lummel M, Derksen RH. et al. Interaction of beta2-glycoprotein I with members of the low density lipoprotein receptor family. J Thromb Haemost 2006; 4 (08) 1680-1690
    CrossrefPubMedGoogle Scholar
  • 63 Alves JD, Ames PRJ, Donohue S. et al. Antibodies to high-density lipoprotein and β2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arth Rheum 2002; 46: 2686-2694
    CrossrefPubMedGoogle Scholar
  • 64 Iuliano L, Praticò D, Ferro D. et al. Enhanced lipid peroxidation in patients positive for antiphospholipid antibodies. Blood 1997; 90 (10) 3931-3935
    CrossrefPubMedGoogle Scholar
  • 65 Hasunuma Y, Matsuura E, Makita Z, Katahira T, Nishi S, Koike T. Involvement of β 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 1997; 107 (03) 569-573
    CrossrefPubMedGoogle Scholar
  • 66 An T, Miller YI, Hansen LF, Kesaniemi YA, Witztum JL, Horkko S. A natural antibody to oxidized cardiolipin binds to oxidized low-density lipoprotein, apoptotic cells, and atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2006; 26 (09) 2096-2102
    CrossrefPubMedGoogle Scholar
  • 67 Charakida M, Besler C, Batuca JR. et al. Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome. JAMA 2009; 302 (11) 1210-1217
    CrossrefPubMedGoogle Scholar
  • 68 Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993; 341 (8850): 923-925
    CrossrefPubMedGoogle Scholar
  • 69 Pengo V, Bison E, Ruffatti A, Iliceto S. Antibodies to oxidized LDL/β2-glycoprotein I in antiphospholipid syndrome patients with venous and arterial thromboembolism. Thromb Res 2008; 122 (04) 556-559
    CrossrefPubMedGoogle Scholar
  • 70 Whitelegge J. Structural biology. Up close with membrane lipid-protein complexes. Science 2011; 334 (6054): 320-321
    CrossrefPubMedGoogle Scholar
  • 71 Perez-Sanchez C, Ruiz-Limon P, Aguirre MA. et al. Mitochondrial dysfunction in antiphospholipid syndrome: implications in the pathogenesis of the disease and effects of coenzyme Q(10) treatment. Blood 2012; 119 (24) 5859-5870
    CrossrefPubMedGoogle Scholar
  • 72 Kim J, Gupta R, Blanco LP. et al. VDAC oligomers form mitochondrial pores to release mtDNA fragments and promote lupus-like disease. Science 2019; 366 (6472): 1531-1536
    CrossrefPubMedGoogle Scholar
  • 73 Lood C, Amisten S, Gullstrand B. et al. Platelet transcriptional profile and protein expression in patients with systemic lupus erythematosus: up-regulation of the type I interferon system is strongly associated with vascular disease. Blood 2010; 116 (11) 1951-1957
    CrossrefPubMedGoogle Scholar
  • 74 Denny MF, Thacker S, Mehta H. et al. Interferon-α promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood 2007; 110 (08) 2907-2915
    CrossrefPubMedGoogle Scholar
  • 75 Canaud G, Bienaimé F, Tabarin F. et al. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med 2014; 371 (04) 303-312
    CrossrefPubMedGoogle Scholar
  • 76 Soltesz P, Der H, Veres K. et al. Immunological features of primary anti-phospholipid syndrome in connection with endothelial dysfunction. Rheumatology (Oxford) 2008; 47 (11) 1628-1634
    CrossrefPubMedGoogle Scholar
  • 77 Hurtado V, Montes R, Gris J-C. et al. Autoantibodies against EPCR are found in antiphospholipid syndrome and are a risk factor for fetal death. Blood 2004; 104 (05) 1369-1374
    CrossrefPubMedGoogle Scholar
  • 78 Li W, Zheng X, Gu J-M. et al. Extraembryonic expression of EPCR is essential for embryonic viability. Blood 2005; 106 (08) 2716-2722
    CrossrefPubMedGoogle Scholar
  • 79 Pötzsch B, Kawamura H, Preissner KT, Schmidt M, Seelig C, Müller-Berghaus G. Acquired protein C dysfunction but not decreased activity of thrombomodulin is a possible marker of thrombophilia in patients with lupus anticoagulant. J Lab Clin Med 1995; 125 (01) 56-65
    PubMedGoogle Scholar
  • 80 Field SL, Chesterman CN, Hogg PJ. Dependence on prothrombin for inhibition of activated protein C activity by lupus antibodies. Thromb Haemost 2000; 84 (06) 1132-1133
    Article in Thieme ConnectPubMedGoogle Scholar
  • 81 Galli M, Ruggeri L, Barbui T. Differential effects of anti-beta2-glycoprotein I and antiprothrombin antibodies on the anticoagulant activity of activated protein C. Blood 1998; 91 (06) 1999-2004
    CrossrefPubMedGoogle Scholar
  • 82 Mercier E, Quere I, Mares P, Gris J-C. Primary recurrent miscarriages: anti-β2-glycoprotein I IgG antibodies induce an acquired activated protein C resistance that can be detected by the modified activated protein C resistance test. Blood 1998; 92 (08) 2993-2994
    CrossrefPubMedGoogle Scholar
  • 83 Sato Y, Sugi T, Sakai R. Antigenic binding sites of anti-protein S autoantibodies in patients with recurrent pregnancy loss. Res Pract Thromb Haemost 2018; 2 (02) 357-365
    CrossrefPubMedGoogle Scholar
  • 84 Meroni PL, Borghi MO, Grossi C, Chighizola CB, Durigutto P, Tedesco F. Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases?. Nat Rev Rheumatol 2018; 14 (07) 433-440
    CrossrefPubMedGoogle Scholar
  • 85 Redecha P, Tilley R, Tencati M. et al. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood 2007; 110 (07) 2423-2431
    CrossrefPubMedGoogle Scholar
  • 86 Girardi G, Berman J, Redecha P. et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003; 112 (11) 1644-1654
    CrossrefPubMedGoogle Scholar
  • 87 Carmona F, Lázaro I, Reverter JC. et al. Impaired factor XIIa-dependent activation of fibrinolysis in treated antiphospholipid syndrome gestations developing late-pregnancy complications. Am J Obstet Gynecol 2006; 194 (02) 457-465
    CrossrefPubMedGoogle Scholar
  • 88 McCrae KR, DeMichele AM, Pandhi P. et al. Detection of antitrophoblast antibodies in the sera of patients with anticardiolipin antibodies and fetal loss. Blood 1993; 82 (09) 2730-2741
    CrossrefPubMedGoogle Scholar
  • 89 Zussman R, Xu LY, Damani T. et al. Antiphospholipid antibodies can specifically target placental mitochondria and induce ROS production. J Autoimmun 2020; 111: 102437
    CrossrefPubMedGoogle Scholar
  • 90 Mulla MJ, Pasternak MC, Salmon JE, Chamley LW, Abrahams VM. Role of NOD2 in antiphospholipid antibody-induced and bacterial MDP amplification of trophoblast inflammation. J Autoimmun 2019; 98: 103-112
    CrossrefPubMedGoogle Scholar
  • 91 Fleck RA, Rapaport SI, Rao LVH. Anti-prothrombin antibodies and the lupus anticoagulant. Blood 1988; 72 (02) 512-519
    CrossrefPubMedGoogle Scholar
  • 92 Chinnaraj M, Planer W, Pengo V, Pozzi N. Discovery and characterization of 2 novel subpopulations of aPS/PT antibodies in patients at high risk of thrombosis. Blood Adv 2019; 3 (11) 1738-1749
    CrossrefPubMedGoogle Scholar
  • 93 Field SL, Hogg PJ, Daly EB. et al. Lupus anticoagulants form immune complexes with prothrombin and phospholipid that can augment thrombin production in flow. Blood 1999; 94 (10) 3421-3431
    CrossrefPubMedGoogle Scholar
  • 94 Bizzaro N, Ghirardello A, Zampieri S. et al. Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15-year longitudinal study. J Thromb Haemost 2007; 5 (06) 1158-1164
    CrossrefPubMedGoogle Scholar
  • 95 Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost 2014; 111 (02) 354-364
    Article in Thieme ConnectPubMedGoogle Scholar
  • 96 Hwang K-K, Grossman JM, Visvanathan S. et al. Identification of anti-thrombin antibodies in the antiphospholipid syndrome that interfere with the inactivation of thrombin by antithrombin. J Immunol 2001; 167 (12) 7192-7198
    CrossrefPubMedGoogle Scholar
  • 97 Bajaj SP, Rapaport SI, Fierer DS, Herbst KD, Schwartz DB. A mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome. Blood 1983; 61 (04) 684-692
    CrossrefPubMedGoogle Scholar
  • 98 Su Z, Izumi T, Thames EH, Lawson JH, Ortel TL. Antiphospholipid antibodies after surgical exposure to topical bovine thrombin. J Lab Clin Med 2002; 139 (06) 349-356
    CrossrefPubMedGoogle Scholar
  • 99 Amengual O, Atsumi T, Khamashta MA, Hughes GRV. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998; 79 (02) 276-281
    Article in Thieme ConnectPubMedGoogle Scholar
  • 100 Williams FMK, Parmar K, Hughes GRV, Hunt BJ. Systemic endothelial cell markers in primary antiphospholipid syndrome. Thromb Haemost 2000; 84 (05) 742-746
    Article in Thieme ConnectPubMedGoogle Scholar
  • 101 Betapudi V, Lominadze G, Hsi L, Willard B, Wu M, McCrae KR. Anti-β2GPI antibodies stimulate endothelial cell microparticle release via a nonmuscle myosin II motor protein-dependent pathway. Blood 2013; 122 (23) 3808-3817
    CrossrefPubMedGoogle Scholar
  • 102 Bidot CJ, Jy W, Horstman LL. et al. Factor VII/VIIa: a new antigen in the anti-phospholipid antibody syndrome. Br J Haematol 2003; 120 (04) 618-626
    CrossrefPubMedGoogle Scholar
  • 103 Artim-Esen B, Pericleous C, Mackie I. et al. Anti-factor Xa antibodies in patients with antiphospholipid syndrome and their effects upon coagulation assays. Arthritis Res Ther 2015; 17: 47
    CrossrefPubMedGoogle Scholar
  • 104 Giannakopoulos B, Gao L, Qi M. et al. Factor XI is a substrate for oxidoreductases: enhanced activation of reduced FXI and its role in antiphospholipid syndrome thrombosis. J Autoimmun 2012; 39 (03) 121-129
    CrossrefPubMedGoogle Scholar
  • 105 Bertolaccini ML, Mepani K, Sanna G, Hughes GRV, Khamashta MA. Factor XII autoantibodies as a novel marker for thrombosis and adverse obstetric history in patients with systemic lupus erythematosus. Ann Rheum Dis 2007; 66 (04) 533-536
    CrossrefPubMedGoogle Scholar
  • 106 Harris SL, Jones DW, Gallimore MJ, Nicholls PJ, Winter M. The antigenic binding site(s) of antibodies to factor XII associated with the antiphospholipid syndrome. J Thromb Haemost 2005; 3 (05) 969-975
    CrossrefPubMedGoogle Scholar
  • 107 Sugi T, McIntyre JA. Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex. Blood 1995; 86 (08) 3083-3089
    CrossrefPubMedGoogle Scholar
  • 108 Sugi T, McIntyre JA. Autoantibodies to kininogen-phosphatidylethanolamine complexes augment thrombin-induced platelet aggregation. Thromb Res 1996; 84 (02) 97-109
    CrossrefPubMedGoogle Scholar
  • 109 Ames PRJ, Iannaccone L, Alves JD, Margarita A, Lopez LR, Brancaccio V. Factor XIII in primary antiphospholipid syndrome. J Rheumatol 2005; 32 (06) 1058-1062
    PubMedGoogle Scholar
  • 110 Karmochkine M, Boffa MC, Piette JC. et al. Increase in plasma thrombomodulin in lupus erythematosus with antiphospholipid antibodies. Blood 1992; 79 (03) 837-838
    CrossrefPubMedGoogle Scholar
  • 111 Arachchillage DRJ, Efthymiou M, Mackie IJ, Lawrie AS, Machin SJ, Cohen H. Anti-protein C antibodies are associated with resistance to endogenous protein C activation and a severe thrombotic phenotype in antiphospholipid syndrome. J Thromb Haemost 2014; 12 (11) 1801-1809
    CrossrefPubMedGoogle Scholar
  • 112 Atsumi T, Khamashta MA, Amengual O. et al. Binding of anticardiolipin antibodies to protein C via β2-glycoprotein I (β2-GPI): a possible mechanism in the inhibitory effect of antiphospholipid antibodies on the protein C system. Clin Exp Immunol 1998; 112 (02) 325-333
    CrossrefPubMedGoogle Scholar
  • 113 Zuily S, de Laat B, Guillemin F. et al. Anti-domain I β2-glycoprotein I antibodies and activated protein C resistance predict thrombosis in antiphospholipid syndrome: TAC(1)T study. J Appl Lab Med 2020; 5 (06) 1242-1252
    CrossrefPubMedGoogle Scholar
  • 114 Crowther MA, Johnston M, Weitz J, Ginsberg JS. Free protein S deficiency may be found in patients with antiphospholipid antibodies who do not have systemic lupus erythematosus. Thromb Haemost 1996; 76 (05) 689-691
    Article in Thieme ConnectPubMedGoogle Scholar
  • 115 Rossetto V, Spiezia L, Franz F. et al. The role of antiphospholipid antibodies toward the protein C/protein S system in venous thromboembolic disease. Am J Hematol 2009; 84 (09) 594-596
    CrossrefPubMedGoogle Scholar
  • 116 Nojima J, Kuratsune H, Suehisa E. et al. Acquired activated protein C resistance associated with anti-protein S antibody as a strong risk factor for DVT in non-SLE patients. Thromb Haemost 2002; 88 (05) 716-722
    PubMedGoogle Scholar
  • 117 Rosing J, Maurissen LF, Tchaikovski SN, Tans G, Hackeng TM. Protein S is a cofactor for tissue factor pathway inhibitor. Thromb Res 2008; 122 (Suppl. 01) S60-S63
    CrossrefPubMedGoogle Scholar
  • 118 Adams MJ, Palatinus AA, Harvey AM, Khalafallah AA. Impaired control of the tissue factor pathway of blood coagulation in systemic lupus erythematosus. Lupus 2011; 20 (14) 1474-1483
    CrossrefPubMedGoogle Scholar
  • 119 Shibata S, Harpel PC, Gharavi A, Rand J, Fillit H. Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes. Blood 1994; 83 (09) 2532-2540
    CrossrefPubMedGoogle Scholar
  • 120 Hajjar KA. The biology of annexin A2: from vascular fibrinolysis to innate immunity. Trans Am Clin Climatol Assoc 2015; 126: 144-155
    PubMedGoogle Scholar
  • 121 Cugno M, Cabibbe M, Galli M. et al. Antibodies to tissue-type plasminogen activator (tPA) in patients with antiphospholipid syndrome: evidence of interaction between the antibodies and the catalytic domain of tPA in 2 patients. Blood 2004; 103 (06) 2121-2126
    CrossrefPubMedGoogle Scholar
  • 122 Singh NK, Gupta A, Behera DR, Dash D. Elevated plasminogen activator inhibitor type-1 (PAI-1) as contributing factor in pathogenesis of hypercoagulable state in antiphospholipid syndrome. Rheumatol Int 2013; 33 (09) 2331-2336
    CrossrefPubMedGoogle Scholar
  • 123 Yamazaki M, Asakura H, Jokaji H. et al. Plasma levels of lipoprotein(a) are elevated in patients with the antiphospholipid antibody syndrome. Thromb Haemost 1994; 71 (04) 424-427
    Article in Thieme ConnectPubMedGoogle Scholar
  • 124 Salle V, Sagnier A, Diouf M. et al. Prevalence of anti-S100A10 antibodies in antiphospholipid syndrome patients. Thromb Res 2019; 179: 15-19
    CrossrefPubMedGoogle Scholar
  • 125 Yang CD, Hwang KK, Yan W. et al. Identification of anti-plasmin antibodies in the antiphospholipid syndrome that inhibit degradation of fibrin. J Immunol 2004; 172 (09) 5765-5773
    CrossrefPubMedGoogle Scholar
  • 126 Ząbczyk M, Celińska-Löwenhoff M, Plens K, Iwaniec T, Musiał J, Undas A. Antiphosphatidylserine/prothrombin complex antibodies as a determinant of prothrombotic plasma fibrin clot properties in patients with antiphospholipid syndrome. J Thromb Haemost 2019; 17 (10) 1746-1755
    CrossrefPubMedGoogle Scholar
  • 127 Chaturvedi S, Braunstein EM, Yuan X. et al. Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood 2020; 135 (04) 239-251
    CrossrefPubMedGoogle Scholar
  • 128 Grosso G, Vikerfors A, Woodhams B. et al. Thrombin activatable fibrinolysis inhibitor (TAFI) - A possible link between coagulation and complement activation in the antiphospholipid syndrome (APS). Thromb Res 2017; 158: 168-173
    CrossrefPubMedGoogle Scholar
  • 129 Chaturvedi S, Braunstein EM, Brodsky RA. Antiphospholipid syndrome: complement activation, complement gene mutations, treatment implications. J Thromb Haemost 2021; 19 (03) 607-616
    CrossrefPubMedGoogle Scholar
  • 130 Hamilton KK, Hattori R, Esmon CT, Sims PJ. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem 1990; 265 (07) 3809-3814
    CrossrefPubMedGoogle Scholar
  • 131 Ikeda K, Nagasawa K, Horiuchi T, Tsuru T, Nishizaka H, Niho Y. C5a induces tissue factor activity on endothelial cells. Thromb Haemost 1997; 77 (02) 394-398
    Article in Thieme ConnectPubMedGoogle Scholar
  • 132 Woodruff MC, Ramonell RP, Nguyen DC. et al. Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. Nat Immunol 2020; 21 (12) 1506-1516
    CrossrefPubMedGoogle Scholar
  • 133 Guey B, Wischnewski M, Decout A. et al. BAF restricts cGAS on nuclear DNA to prevent innate immune activation. Science 2020; 369 (6505): 823-828
    CrossrefPubMedGoogle Scholar
  • 134 Krienke C, Kolb L, Diken E. et al. A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science 2021; 371 (6525): 145-153
    CrossrefPubMedGoogle Scholar